RELATED FACTORS TO LDL-C GOAL ACHIEVEMENT IN OLDER OFFICIALS ACCORDING TO 2019 EUROPEAN SOCIETY OF CARDIOLOGY/ EUROPEAN ATHEROSCLEROSIS SOCIETY GUIDELINES IN THE OFFICER HEALTHCARE DEPARTMENT OF CA MAU PROVINCE
DOI:
https://doi.org/10.59354/ydth175.2021.97Keywords:
low-density lipoprotein cholesterol (LDL-C), elderly, SCORE Risk ChartsAbstract
Background: Intensive control of low-density lipoprotein cholesterol (LDL-C) prevents cardiovascular outcomes in the elderly.
Objectives: To assess related factors to LDL-C goal achievement in older officials at Healthcare department of the Provincial Party Committee in Ca Mau province as recommended by European Society of Cardiology/European Atherosclerosis Society 2019 (ESC/EAS 2019).
Methods: Cross- sectional study in 674 individuals, the male/female ratio was 4,6/1, the mean age was 69,28. They were collected clinical information, medical history and test LDL-C level to assess cardiovascular risk and related factors to LDL-C control status.
Results: The prevalence of LDL-C goal achievement was 22.7% according to ESC/EAS 2019 guidelines. Non-smoking people had higher ratio of achievement (OR 2.03, CI 95% 1.04 – 3.97, p=0.038). Those with the treatment compliance had higher ratio of achievement (OR 7.78, CI 95% 3.69 – 16.42, p <0.001). Compared with individuals treated with atorvastatin, those with rosuvastatin had a higher rate of reaching LDL-C goal (OR 2.08, CI 95% 1.02 – 4.25, p=0.044). Those with moderate risk had higher chance of LDL-C achievement (OR 5.69, CI 95% 2.84 – 11.38, p <0.001).
Conclusions: The ratio of reaching the LDL-C as recommended by ESC/EAS 2019 in the elderly in the officer healthcare department of Provincial Party Committee in Ca Mau province was not high. Non-smokers, adherence with treatment, treated with rosuvastatin (compared with atorvastatin) were associated factors with higher achievement of LDL-C target. People at moderate cardiovascular risk have a higher rate of LDL-C control than people at very high risk.
References
Đỗ Thị Nguyên, Hàn Đức Đạt, Hà Phạm Trọng Khang và cs (2020). Nghiên cứu thực trạng kiểm soát LDL-C ở cán bộ thuộc diện quản lý sức khỏe tỉnh ủy Bình Phước. Tạp chí y học thành phố Hồ Chí Minh, 24 (5): 231-236.
Quách Tấn Đạt, Phạm Hòa Bình, Nguyễn Văn Tân (2021). Thực trạng điều trị rối loạn lipid máu ở bệnh nhân hội chứng vành cấp cao tuổi tại bệnh viện Thống Nhất. Tạp chí y học thành phố Hồ Chí Minh, 25 (2):140 - 146.
Trần Thanh Bình, Lê Thị Kim Oanh, Trần Thị Thu Hằng và cs (2019). Rối loạn lipid ở bệnh nhân cao tuổi đái tháo đường típ 2 tại phòng khám A1, Bệnh Viện Thống Nhất. Tạp chí y học thành phố Hồ Chí Minh, 23 (3):237 - 243.
Nguyễn Ngọc Thanh Vân, Châu Ngọc Hoa (2018). Tình hình kiểm soát huyết áp, đường huyết và lipid máu trên bệnh nhân tăng huyết áp có đái tháo đường typ 2 mới mắc. Tạp chí y học thành phố Hồ Chí Minh, 22 (1):357 - 362.
Yazdanyar A, Newman AB (2009). The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med, 25(4):563-vii.
Mach F, Baigent C, Catapano A L et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 41 (1):111-188.
Kim H S, Wu Y, Lin S J, Deerochanawong C et al. (2008). Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin, 24 (7):1951-63.
Yang Y S, Lee S Y, Kim J S et al. (2020). Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments. Endocrinol Metab (Seoul), 35 (2):367-376.
Hallit S, Zoghbi M, Hallit R et al. (2017). Effect of exclusive cigarette smoking and in combination with waterpipe smoking on lipoproteins. J Epidemiol Glob Health, 7 (4):269-275.
Clearfield M B, Amerena J, Bassand J P et al. (2006). Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia-- Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials, 7:35.
